Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.

The Nasdaq Composite has been a goldmine for investors, powered by technology, artificial intelligence, and visionary ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...

President Trump isn't a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump recently called Powell a "major loser" on a social media post and demanded ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June ...

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Di ...